Expanding API manufacturing operations: Cambrex and Asymchem
Cambrex expands API manufacturing capacity at flagship US facility and Asymchem completes construction of two new Chinese API production sites.
List view / Grid view
Cambrex expands API manufacturing capacity at flagship US facility and Asymchem completes construction of two new Chinese API production sites.
Evonetix has been granted a European patent for its silicon chips that leverage semiconductor technology to thermally control DNA synthesis.
The closing of two biologics acquisitions will help Recipharm establish itself in the advanced therapy medicinal products space.
7 April 2022 | By Charles River
Watch experts discuss key aspects of microbial investigations, helping you to understand and implement the new PDA Technical Report 88, and sharing their experience of investigating various microbial events in the real world.
Catalent announces the expansion of its biologics development and manufacturing capability by purchasing a new facility, currently under construction in Oxford, UK.
FUJIFILM Diosynth Biotechnologies will run the cell therapy manufacturing facility, acquired for $100mn from Atara Biotherapeutics, as part of its global network.
In a £1.3 million collaborative project Symbiosis and the Cell and Gene Therapy (CGT) Catapult reduced viral vector manufacturing times by more than 25 percent.
Pre-clinical research demonstrates the potential of a new implantable biotechnology called MASTER to produce and release CAR T cells in vivo.
New pre-clinical research suggests a 24-hour manufacturing process that produces fewer, more potent CAR T cells could be the key to both reducing production timelines and improving patient access to cell therapies.
Ami Polymer are experts in manufacture of silicone tubing, hose and single use assembly with PPE components, which is demanded in pharma/biopharma industry.
Global biotechnology company WuXi has demonstrated the success of the CRDMO business model by publishing news of its bumper projects and revenues fuelled by innovative technology platforms in 2021.
The new manufacturing facility will support production and development of cannabis-based medicines in the UK.
25 March 2022 | By SCIEX
Exploring the complexities of nitrosamines to enhance understanding and overall management, with a focus on nitrosamine drug substance-related impurities (NDSRIs).
Compliant, reliable, safe, and contained conveying of powders and pills in tablet manufacturing replaces manual handling or mechanical conveying.
In a new paper, Lumen Bioscience detailed how spirulina can be genetically engineered for to rapidly produce large quantities of biologic drugs.